Armata Pharmaceuticals, Inc.
ARMP
$1.42
$0.06815.04%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.24% | 34.92% | -10.71% | -7.28% | -17.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.24% | 34.92% | -10.71% | -7.28% | -17.77% |
| Cost of Revenue | -0.56% | 80.00% | 38.02% | 34.56% | 45.16% |
| Gross Profit | 2.01% | -87.76% | -44.43% | -41.29% | -56.90% |
| SG&A Expenses | 13.17% | 26.84% | 61.99% | 53.78% | 56.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.83% | 2.74% | 3.82% | -0.26% | 6.98% |
| Operating Income | -3.78% | 0.39% | -5.34% | -0.65% | -10.68% |
| Income Before Tax | 72.60% | 30.50% | -81.37% | -86.65% | -87.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.60% | 30.50% | -81.37% | -86.65% | -87.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.60% | 30.50% | -81.37% | -86.65% | -87.03% |
| EBIT | -3.78% | 0.39% | -5.34% | -0.65% | -10.68% |
| EBITDA | -2.99% | 1.17% | -4.91% | -0.24% | -10.72% |
| EPS Basic | 72.63% | 30.58% | -81.14% | -86.31% | -76.58% |
| Normalized Basic EPS | -20.79% | -16.27% | -22.34% | -11.31% | -10.87% |
| EPS Diluted | 18.60% | 4.82% | -113.94% | -91.13% | -81.91% |
| Normalized Diluted EPS | -4.36% | -12.67% | -19.03% | -2.51% | -1.98% |
| Average Basic Shares Outstanding | 0.24% | 0.22% | 0.19% | 0.18% | 5.27% |
| Average Diluted Shares Outstanding | 15.08% | 1.17% | 1.15% | 14.38% | 20.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |